Progyny (PGNY) Cost of Revenue (2018 - 2026)

Progyny (PGNY) has reported Cost of Revenue for 9 consecutive years, with $245.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue fell 1.13% year-over-year to $245.4 million; the TTM figure through Mar 2026 stood at $981.4 million (up 3.69% YoY), while the FY2025 annual figure was $984.2 million, up 7.69% from the prior year.
• Cost of Revenue improved to $245.4 million in Q1 2026 per PGNY's latest filing, from $241.5 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $253.9 million in Q2 2025 and bottomed at $139.3 million in Q1 2022.
• Historically, Cost of Revenue has averaged $212.5 million across 5 years, with a median of $218.7 million in 2023.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 69.92% — and 2026, when it declined 1.13%.
• Progyny's Cost of Revenue stood at $169.8 million in 2022, then rose by 25.45% to $213.0 million in 2023, then gained by 10.3% to $235.0 million in 2024, then advanced by 2.78% to $241.5 million in 2025, then advanced by 1.62% to $245.4 million in 2026.
• Business Quant data shows PGNY's Cost of Revenue at $245.4 million in Q1 2026, $241.5 million in Q4 2025, and $240.5 million in Q3 2025.